Enzo Biochem, Inc. (NYSE: ENZ)’s stock price has decreased by -5.50 compared to its previous closing price of 1.09. However, the company has seen a -8.04% decrease in its stock price over the last five trading sessions. zacks.com reported 2024-06-20 that Discover why Zacks rates Enzo Biochem as “Neutral”, being the first on Wall Street to initiate coverage on the stock. Explore ENZ’s notable revenue growth and financial health amid market challenges.
Is It Worth Investing in Enzo Biochem, Inc. (NYSE: ENZ) Right Now?
The stock has a 36-month beta value of 0.76. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ENZ is 35.78M, and at present, short sellers hold a 1.57% of that float. On June 28, 2024, the average trading volume of ENZ was 123.35K shares.
ENZ’s Market Performance
The stock of Enzo Biochem, Inc. (ENZ) has seen a -8.04% decrease in the past week, with a -17.60% drop in the past month, and a -18.90% fall in the past quarter. The volatility ratio for the week is 6.31%, and the volatility levels for the past 30 days are at 7.20% for ENZ. The simple moving average for the past 20 days is -9.33% for ENZ’s stock, with a -18.63% simple moving average for the past 200 days.
Analysts’ Opinion of ENZ
Many brokerage firms have already submitted their reports for ENZ stocks, with Rodman & Renshaw repeating the rating for ENZ by listing it as a “Mkt Outperform.” The predicted price for ENZ in the upcoming period, according to Rodman & Renshaw is $5 based on the research report published on October 18, 2011 of the previous year 2011.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see ENZ reach a price target of $14. The rating they have provided for ENZ stocks is “Mkt Outperform” according to the report published on September 23rd, 2009.
Lazard Capital gave a rating of “Buy” to ENZ, setting the target price at $19 in the report published on September 13th of the previous year.
ENZ Trading at -6.84% from the 50-Day Moving Average
After a stumble in the market that brought ENZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.79% of loss for the given period.
Volatility was left at 7.20%, however, over the last 30 days, the volatility rate increased by 6.31%, as shares sank -12.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.30% lower at present.
During the last 5 trading sessions, ENZ fell by -8.93%, which changed the moving average for the period of 200-days by -23.88% in comparison to the 20-day moving average, which settled at $1.1290. In addition, Enzo Biochem, Inc. saw -25.90% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ENZ
Current profitability levels for the company are sitting at:
- 1.18 for the present operating margin
- -2.82 for the gross margin
The net margin for Enzo Biochem, Inc. stands at 9.48. The total capital return value is set at 0.08. Equity return is now at value -112.37, with -51.80 for asset returns.
Based on Enzo Biochem, Inc. (ENZ), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -9.05. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -0.66.
Currently, EBITDA for the company is -12.12 million with net debt to EBITDA at -6.26. When we switch over and look at the enterprise to sales, we see a ratio of -0.62. The receivables turnover for the company is 1.2for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.50.
Conclusion
To sum up, Enzo Biochem, Inc. (ENZ) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
